S&P 500   5,137.63 (+0.81%)
DOW   39,091.09 (+0.24%)
QQQ   445.48 (+1.48%)
AAPL   179.70 (-0.58%)
MSFT   414.95 (+0.32%)
META   502.13 (+2.45%)
GOOGL   137.96 (-0.36%)
AMZN   178.59 (+1.04%)
TSLA   202.74 (+0.43%)
NVDA   819.14 (+3.54%)
NIO   5.79 (+0.70%)
AMD   201.38 (+4.60%)
BABA   74.54 (+0.69%)
T   16.99 (+0.35%)
F   12.43 (-0.08%)
MU   95.64 (+5.55%)
CGC   3.19 (-3.04%)
GE   158.80 (+1.22%)
DIS   111.85 (+0.24%)
AMC   4.38 (+1.39%)
PFE   26.62 (+0.23%)
PYPL   60.66 (+0.53%)
XOM   105.68 (+1.11%)
S&P 500   5,137.63 (+0.81%)
DOW   39,091.09 (+0.24%)
QQQ   445.48 (+1.48%)
AAPL   179.70 (-0.58%)
MSFT   414.95 (+0.32%)
META   502.13 (+2.45%)
GOOGL   137.96 (-0.36%)
AMZN   178.59 (+1.04%)
TSLA   202.74 (+0.43%)
NVDA   819.14 (+3.54%)
NIO   5.79 (+0.70%)
AMD   201.38 (+4.60%)
BABA   74.54 (+0.69%)
T   16.99 (+0.35%)
F   12.43 (-0.08%)
MU   95.64 (+5.55%)
CGC   3.19 (-3.04%)
GE   158.80 (+1.22%)
DIS   111.85 (+0.24%)
AMC   4.38 (+1.39%)
PFE   26.62 (+0.23%)
PYPL   60.66 (+0.53%)
XOM   105.68 (+1.11%)
S&P 500   5,137.63 (+0.81%)
DOW   39,091.09 (+0.24%)
QQQ   445.48 (+1.48%)
AAPL   179.70 (-0.58%)
MSFT   414.95 (+0.32%)
META   502.13 (+2.45%)
GOOGL   137.96 (-0.36%)
AMZN   178.59 (+1.04%)
TSLA   202.74 (+0.43%)
NVDA   819.14 (+3.54%)
NIO   5.79 (+0.70%)
AMD   201.38 (+4.60%)
BABA   74.54 (+0.69%)
T   16.99 (+0.35%)
F   12.43 (-0.08%)
MU   95.64 (+5.55%)
CGC   3.19 (-3.04%)
GE   158.80 (+1.22%)
DIS   111.85 (+0.24%)
AMC   4.38 (+1.39%)
PFE   26.62 (+0.23%)
PYPL   60.66 (+0.53%)
XOM   105.68 (+1.11%)
S&P 500   5,137.63 (+0.81%)
DOW   39,091.09 (+0.24%)
QQQ   445.48 (+1.48%)
AAPL   179.70 (-0.58%)
MSFT   414.95 (+0.32%)
META   502.13 (+2.45%)
GOOGL   137.96 (-0.36%)
AMZN   178.59 (+1.04%)
TSLA   202.74 (+0.43%)
NVDA   819.14 (+3.54%)
NIO   5.79 (+0.70%)
AMD   201.38 (+4.60%)
BABA   74.54 (+0.69%)
T   16.99 (+0.35%)
F   12.43 (-0.08%)
MU   95.64 (+5.55%)
CGC   3.19 (-3.04%)
GE   158.80 (+1.22%)
DIS   111.85 (+0.24%)
AMC   4.38 (+1.39%)
PFE   26.62 (+0.23%)
PYPL   60.66 (+0.53%)
XOM   105.68 (+1.11%)
NASDAQ:ACXP

Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis

$3.02
+0.15 (+5.23%)
(As of 02:55 PM ET)
Today's Range
$2.82
$3.17
50-Day Range
$2.80
$4.81
52-Week Range
$1.17
$8.82
Volume
59,586 shs
Average Volume
221,079 shs
Market Capitalization
$41.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Acurx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
362.0% Upside
$14.00 Price Target
Short Interest
Healthy
2.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Acurx Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.83) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

391st out of 957 stocks

Pharmaceutical Preparations Industry

183rd out of 440 stocks


ACXP stock logo

About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Stock Price History

ACXP Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ACXP Mar 2024 4.000 call
ACXP Mar 2024 5.000 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ELAB, KIND and RLX among pre-market losers
Acurx Pharmaceuticals: Q3 Earnings Insights
12 Best Day Trading Stocks To Buy
See More Headlines
Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/01/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACXP
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+387.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-12,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.63 per share

Miscellaneous

Free Float
8,908,000
Market Cap
$39.52 million
Optionable
Optionable
Beta
-1.83
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














ACXP Stock Analysis - Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings
or view top-rated stocks.

What is Acurx Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12-month price targets for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 362.0% from the stock's current price.
View analysts price targets for ACXP
or view top-rated stocks among Wall Street analysts.

How have ACXP shares performed in 2024?

Acurx Pharmaceuticals' stock was trading at $3.83 on January 1st, 2024. Since then, ACXP shares have decreased by 20.9% and is now trading at $3.03.
View the best growth stocks for 2024 here
.

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a drop in short interest in February. As of February 15th, there was short interest totaling 301,500 shares, a drop of 12.3% from the January 31st total of 343,700 shares. Based on an average trading volume of 236,800 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short.
View Acurx Pharmaceuticals' Short Interest
.

When is Acurx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ACXP earnings forecast
.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its earnings results on Monday, August, 14th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. During the same period in the prior year, the business posted ($0.26) EPS.

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.

Who are Acurx Pharmaceuticals' major shareholders?

Acurx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.95%), Prospect Financial Services LLC (1.85%), Citadel Advisors LLC (0.00%), Northern Trust Corp (0.12%), Sigma Planning Corp (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends
.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACXP) was last updated on 3/1/2024 by MarketBeat.com Staff